Ken Griffin Cullinan Oncology, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,600 shares of CGEM stock, worth $206,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,600
Previous 8,200
53.66%
Holding current value
$206,892
Previous $83,000
157.83%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CGEM
# of Institutions
118Shares Held
42.8MCall Options Held
12.6KPut Options Held
4.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$126 Million21.33% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$56.1 Million15.23% of portfolio
-
Bvf Inc San Francisco, CA3.2MShares$52.5 Million1.63% of portfolio
-
Blue Owl Capital Holdings LP New York, NY2.92MShares$48 Million13.21% of portfolio
-
Franklin Resources Inc San Mateo, CA2.7MShares$44.3 Million0.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $749M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...